Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc (INM) is a clinical-stage biopharmaceutical leader developing cannabinoid-based therapies for complex medical conditions. This dedicated news hub provides investors and industry observers with timely updates on INM's research milestones, regulatory developments, and strategic initiatives.
Access comprehensive coverage of the company's progress in neurodegenerative, ocular, and dermatological drug development. Our curated news collection features official press releases alongside verified third-party analysis, offering a complete picture of INM's pipeline advancements and intellectual property developments.
Key updates include clinical trial results, regulatory submissions, partnership announcements, and manufacturing innovations related to INM-755, INM-089, and other proprietary candidates. The resource emphasizes INM's unique approach combining cannabinoid pharmacology with advanced delivery systems to address unmet medical needs.
Bookmark this page for streamlined access to essential updates about INM's therapeutic pipeline, patent portfolio expansions, and scientific presentations. Stay informed about the company's progress in developing small molecule therapies through this centralized, regularly updated resource.
InMed Pharmaceuticals reported a robust financial position with $11.5 million in cash as of December 31, 2022, reflecting a year-over-year increase. The company is nearing the enrollment completion of its Phase 2 clinical trial for Epidermolysis Bullosa, targeting 20 patients. Revenue from its BayMedica segment surged to $0.8 million, a 198% increase compared to the previous fiscal year, driven by enhanced marketing efforts. The net loss for the six months ending December 31, 2022, was reduced to $5.6 million from $7.3 million in the same period last year, indicating improved operational efficiency. InMed aims to leverage its strong cash reserves to achieve critical milestones in 2023.
InMed Pharmaceuticals, a leader in cannabinoid research, has submitted a Form 12b-25 to the SEC regarding delays in filing its financial statements for the period ended December 31, 2022. The delay stems from a change in auditors. The company expects to complete the necessary filings within the five-day extension period. Additionally, InMed has applied for a temporary management cease trade order (MCTO) in British Columbia to prohibit trading by its CEO and CFO until disclosures are filed. The MCTO, if approved, will allow public trading to continue.
FAQ
What is the current stock price of Inmed Pharmaceuticals (INM)?
What is the market cap of Inmed Pharmaceuticals (INM)?
